Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + aflibercept
- Development stage
- Unknown
- Lead developer
- University of Alexandria
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Ophthalmic
01
Overview
This combination therapy consists of the oral sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin and the intravitreal vascular endothelial growth factor (VEGF) inhibitor aflibercept. It is being investigated by Alexandria University as a treatment for center-involved diabetic macular edema (DME). Dapagliflozin, typically used for glycemic control in type 2 diabetes, is hypothesized to act as an adjunct to standard-of-care anti-VEGF therapy by further reducing retinal thickness through systemic glucose lowering and potential local osmotic or anti-inflammatory effects. Aflibercept works by binding to VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby inhibiting the signaling pathways that lead to vascular leakage and macular swelling.
- Other names
- anti-VEGF-Alexandria University-diabetic macular edemaDapagliflozin + AfliberceptDapagliflozin + anti-VEGF
02
Targets
VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)PGF (Placental Growth Factor)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on dapagliflozin + aflibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + aflibercept.